Testing for 22q11 microdeletion in 146 fetuses with nuchal translucency above the 99th percentile and a normal karyotype

Research output: Contribution to journal › Journal article › Research › peer-review

  • Charlotte Kvist Lautrup
  • Susanne Kjaergaard
  • Karen Brøndum-Nielsen
  • Christina Fagerberg
  • Jens Michael Hertz
  • Petersen, Olav Bennike Bjørn
  • Mette Warming Jørgensen
  • Ida Vogel
The aim of this study was to examine the value of testing for a 22q11 microdeletion in fetuses with nuchal translucency (NT) above the 99th percentile (>3.5 mm). A 22q11 microdeletion results in the development of 22q11 deletion syndrome, a spectrum of disorders also known as DiGeorge/Velocardiofacial syndrome. A total of 146 pregnancies met the inclusion criteria of NT >3.5 mm between 11+2 and 13+6 weeks' gestation, no structural malformation and normal karyotype. Chorionic villi samples were tested with either multiplex ligation-dependent probe amplification (MLPA) or fluorescent in situ hybridization (FISH) analysis for 22q11 microdeletion. None were diagnosed with the microdeletion. The estimated prevalence of 22q11 microdeletion in these otherwise normal fetuses with increased NT is below 2.7%.
Original languageEnglish
JournalActa Obstetricia et Gynecologica Scandinavica
Volume87
Issue number11
Pages (from-to)1252-1255
ISSN0001-6349
DOIs
Publication statusPublished - 2008

Bibliographical note

Keywords: Adult; Chorionic Villi Sampling; Chromosome Deletion; Chromosomes, Human, Pair 22; Female; Gene Deletion; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Neck; Nuchal Translucency Measurement; Pregnancy; Pregnancy Outcome; Pregnancy Trimester, First; Prenatal Diagnosis; Retrospective Studies; Syndrome; Ultrasonography, Prenatal

ID: 10486456